Moreover, SGLT2 inhibitors have been used to treat patients with T2DM to reduce the risk of CV events, including HF, and it is clear that the mechanism by which SGLT2 inhibitors reduce this risk may not be directly related to improved diabetic status and glycemic control. The gene discussed is SLC5A2; the disease is hydrops fetalis.